

Table of contents

Abbreviations and acronyms	1
Figure index	9
Table index	15
Abstract	17
Resumen	20
Resum	23
Introduction	27
1.1 Cancer	29
1.2 BC epidemiology	30
1.3 BC risk factors	33
1.3.1 Non-modifiable risk factors	33
1.3.1.1 Family history and genetic factors	33
1.3.1.2 Age	33
1.3.1.3 Menarche and menopause	34
1.3.1.4 Breast density	34
1.3.2 Modifiable risk factors	34
1.3.2.1 Reproductive factors	34
1.3.2.2 Hormone factors	35
1.3.2.3 Lifestyle factors	35
1.4 BC screening	36
1.5 BC classification	38
1.5.1 Histological and anatomical classification	38
1.5.2 Pathological classification	41
1.5.3 Molecular classification	42

1.6 BC treatment	46
1.6.1 Surgery and radiotherapy	47
1.6.2 Chemotherapy	48
1.6.3 Hormone therapy	48
1.6.4 Anti-HER2 therapy	49
1.6.5 PI3K inhibitors	51
1.6.6 PARP inhibitors	51
1.6.7 CDK4/6 inhibitors	52
1.6.8 mTOR inhibitors	52
1.6.9 Immunotherapy	53
1.7 MicroRNAs	53
1.7.1 Biogenesis	54
1.7.2 Target regulation	57
1.7.3 Cancer implication	59
1.7.3.1 MiRNA-449 family	64
1.7.4 MiRNAs clinical applicability	73
1.7.4.1 Biomarkers	73
1.7.4.2 Therapeutic tools	76
Objectives	83
Materials and methods	87
3.1 Cell lines and proceedings	89
3.1.1 Cell lines	89
3.1.2 Cell counting	91
3.1.3 Cryopreservation	92
3.2 Drugs	92
3.2.1 Trichostatin A	92
3.2.2 Nicotinamide	93

3.2.3 DOX.....	93
3.3 miRNA and siRNA transient transfections	93
3.4 Gene expression analysis.....	95
3.4.1 RNA extraction and quantification.....	95
3.4.2 Retro-transcription	96
3.4.3 RT-qPCR.....	97
3.5 Protein expression analysis	98
3.5.1 Protein extraction and quantification.....	98
3.5.2 Protein preparation	99
3.5.3 Western blot	99
3.5.4 Western blot quantification	101
3.6 Luciferase reporter assay.....	101
3.7 Cell proliferation and viability assay	103
3.8 Colony formation assay	103
3.9 Transwell assay	104
3.10 Quantification of intracellular DOX uptake	104
3.11 Apoptosis assay.....	105
3.12 <i>In silico</i> analysis.....	106
3.12.1 Kaplan-Meier curves	106
3.12.2 MiRWalk analysis.....	106
3.12.3 MirPath analysis.....	107
3.13 Patient samples.....	107
3.14 Statistical analyses	108
Results	111
4.1 MiRNA-449 family is repressed in TNBC through epigenetic mechanisms	113
4.1.1 MiRNA-449 family is downregulated in TNBC patients and cell lines and its expression is associated with worst OS	113

4.1.2 HDAC1 and SIRT1 are overexpressed in TNBC and inhibit miRNAs-449 expression by histone deacetylation	115
4.1.3 MiRNA-449 family downregulate HDAC1 and SIRT1 expression by a negative feedback loop	119
4.2 MiRNA-449 family modulates TNBC aggressiveness through ACSL4 targeting	122
4.2.1 MiRNA-449 family modulates fatty acid metabolism through ACSL4 direct targeting	122
4.2.2 MiRNAs-449 overexpression inhibits proliferation, colony formation, migration, and invasion through ACSL4 downregulation	127
4.3 MiRNAs-449 modulate DOX response through ACSL4/ ATP-binding cassette superfamily G member 2 (ABCG2) axis.....	132
4.3.1 ACSL4 higher expression is associated with chemotherapy resistance in DOX-resistant cell line and TNBC patients	132
4.3.2 MiRNAs-449 overexpression sensitizes TNBC cells to DOX through ACSL4 downregulation.....	137
4.3.3 MiRNAs-449 overexpression increases intracellular DOX accumulation through ACSL4/ABCG2 axis	141
Discussion.....	147
Conclusions	159
Bibliography	163
Appendix	195